A Chatbot-Powered G8 Screening Intervention to Facilitate Referrals to a Comprehensive Geriatric Assessment Among Older Adults With Cancer

Chatbot Powered G8 Screening Intervention

In this prospective quality improvement study, we will develop and evaluate the feasibility and acceptability of an online patient self-reported G8 screening tool which will allow us to efficiently identify G8 positive older cancer patients to be referred to our Senior Adult Oncology Center (SAOC) for a Comprehensive Geriatric Assessment (CGA).

Study Overview

• Status: Completed
• Conditions: Geriatric Cancer Patients
• Intervention / Treatment: Other: G8 Screening Tool

Detailed Description

We will test the feasibility and acceptability of the online G8 screening tool developed. 100 older new established cancer patients who had used the MyChart G8 will be recruited to provide their feedback on the usability of the screening tool and any related referral and SAOC appointment experience. Among patients with G8 scores ≤ 14, they will be referred to a CGA. We will examine CGA attendance compliance, predictive value of the online collected G8 score with the final frailty designation determined by the CGA, and perceived barriers among CGA non-adherent patients via a brief follow up inquiry.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Sidney Kimmel Cancer Center at Thomas Jefferson University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 61 years and older (Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Cancer patients who are 65 years of age or older coming to the medical oncology department at Thomas Jefferson University for care.

Description

Inclusion Criteria:

• 65 years and older
• New Patient Visit scheduled for Medical Oncology

Exclusion Criteria:

• Inability to answer or have caregiver answer questions on screening tool.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Cancer patients who are 65 years of age or older; An online self-reported G8 screening tool. The tool will have content including: 1) the purpose and benefit of the G8, 2) explanations of each question with examples and probes to help with recall, and 3) next steps after the G8 assessment is completed and how the results might impact their cancer treatments. New established older cancer patients will be invited to interact with the tool.

Other: G8 Screening Tool; Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agree to using the G8 assessment	To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.	At time of visit
Complete the G8 assessment	To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.	At time of visit
3. Complete the referred SAOC visits if they complete the G8 assessment and are screened positive	To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.	After visit

Collaborators and Investigators

• Sponsor: Thomas Jefferson University
• Collaborators: National Cancer Institute (NCI)

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2022
• Primary Completion (Actual): January 1, 2023
• Study Completion (Actual): January 1, 2024

Study Registration Dates

• First Submitted: June 17, 2022
• First Submitted That Met QC Criteria: September 7, 2022
• First Posted (Actual): September 10, 2022

Study Record Updates

• Last Update Posted (Actual): July 31, 2024
• Last Update Submitted That Met QC Criteria: July 29, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 21F.675; 080-27000-S45501 (Other Grant/Funding Number: NCI)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No